ocrelizumab

Ligand id: 7580

Name: ocrelizumab

References
1. Adams CW, Chan AC, Crowley CW, Lowman HB, Nakamura GR, Presta LG. (2004)
Immunoglobulin variants and uses thereof.
Patent number: WO2004056312. Assignee: Genentech, Inc.. Priority date: 16/12/2002. Publication date: 08/07/2004.
2. Hutas G. (2008)
Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies.
Curr Opin Investig Drugs9 (11): 1206-15. [PMID:18951300]
3. Kausar F, Mustafa K, Sweis G, Sawaqed R, Alawneh K, Salloum R, Badaracco M, Niewold TB, Sweiss NJ. (2009)
Ocrelizumab: a step forward in the evolution of B-cell therapy.
Expert Opin Biol Ther9 (7): 889-95. [PMID:19463076]
4. Vugmeyster Y, Beyer J, Howell K, Combs D, Fielder P, Yang J, Qureshi F, Sandlund B, Kawaguchi L, Dummer W et al.. (2005)
Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis.
J. Immunother.28 (3): 212-9. [PMID:15838377]